The Janus kinase (JAK) family of intracellular tyrosine kinases plays a pivotal role in transducing extracellular cytokine signaling, thereby contributing to major processes such as cellular proliferation, homeostasis, and host defense against infection. In RA, certain JAKmediated signaling pathways are dysfunctionally active, leading to enhanced transcription of various proinflammatory genes and aberrant immune responses. In this Interactive Exchange™ program, a panel of expert rheumatologists will discuss the rationale underscoring targeted JAK inhibition, the latest clinical evidence on available and emerging JAK inhibitor therapies, evolving RA treatment guidelines, and challenges surrounding the appropriate and timely use of JAK inhibitors. This interactive program will also allow attendees to direct their own learning by selecting topics, from a predetermined list, for the expert faculty to discuss and debate. Topics will reflect key issues that are relevant to today’s rheumatology practice, including, but not limited to, the initiation and use of JAK inhibitors as monotherapy, selecting among inclass therapeutic options, appropriate sequencing of diseasemodifying antirheumatic drugs (DMARDs) following inadequate treatment response, and clinical complications surrounding the management of patients with moderatetosevere RA. The overall goal of this program is to assist attendees in translating the latest information regarding JAK inhibitor therapy into improved RA management and patient care.

Additional resources are available here: https://www.exchangecme.com/jakresour...

You can also visit http://www.ExchangeCME.com for access to additional video content as well as free CME activities in various therapeutic areas.